RDIF is inviting international scientists and scientific institutions to cooperate on research of real-world data/real-world evidence (RWD/RWE) on safety and efficacy of Sputnik V, Sputnik Light and other vaccines against coronavirus

Press release, 07.10.2021

Moscow, October 7, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) is inviting independent international researchers and scientific institutions to cooperate on real-world studies of safety and efficacy of coronavirus vaccines, including Sputnik V, Sputnik Light and others.

Key study topics:

  • Real-world studies on safety and efficacy of Sputnik V and Sputnik Light;
  • Efficacy factor analysis;
  • Comparative analysis of real-world data on safety and efficacy of Sputnik V, Sputnik Light and other vaccines;
  • Analysis of the real-world data on safety and efficacy of Sputnik Light as a booster.

Applicants conducting or planning to start scientific research in the abovementioned areas are kindly invited to contact RDIF and describe areas of interest and specific cooperation proposals via vaccineresearch@rdif.ru

Monitoring and analysis of the results of the use of Sputnik V and Sputnik Light vaccines as well as scientific research are priorities for RDIF as an investor in the development and international promotion of these vaccines. The Fund is interested in expanding the knowledge of Russian and international scientists, as well as raising public awareness regarding the real-world data on safety and efficacy of Sputnik V, Sputnik Light and other vaccines.

The two-dose Sputnik V vaccine is the world's first registered vaccine against coronavirus. It is the first vaccine based on heterogeneous boosting approach (“vaccine cocktail” using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component). Taking into account the success of this approach to ensure stable and long-term immunity against the new coronavirus infection, RDIF was the first in the world to initiate partnerships with other vaccine manufacturers and to conduct joint research on the combination of the first component of Sputnik V with foreign vaccines.

Single-dose Sputnik Light vaccine is the first component (recombinant human adenovirus 26 serotype (rAd26)) of the Sputnik V vaccine.

RDIF actively promotes cooperation and networking of the international scientific community on the Sputnik V vaccine. In January 2021, RDIF and the Gamaleya Center created the International Scientific Advisory Board on the Sputnik V vaccine, bringing together leading scientists in virology, microbiology and immunology from Argentina, Britain, Croatia, France, Germany, India, Sweden, USA and Russia.

Studies based on analysis of the use of Sputnik V and Sputnik Light vaccines have been published in leading international peer-reviewed medical journals: The Lancet, EClinical Medicine (published by The Lancet), Vaccines, Cell Reports Medicine.

RDIF endorses the publication of new independent studies on the results of vaccination with Sputnik V and Sputnik Light on the general population around the world in leading medical journals.

Sputnik V has a number of key advantages:

  • The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
  • Sputnik V has pioneered the use of heterogeneous boosting (two different vectors for the two shots in a course of vaccination among COVID vaccines). This approach provides for immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
  • The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
  • There are no strong allergies caused by Sputnik V.

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru

For additional information contact:

Alexey Urazov
Russian Direct Investment Fund
Director for External Communications

Mobile: +7 915 312 76 65
E-mail: Alexey.Urazov@rdif.ru

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133